129 P - Serum CA 15-3 in node-negative breast cancer: a marker of prognostic significance?

Autor: Kowalski Dm, A. Dziewulska-Bokiniec, J. Wojtacki, G. Rolka-Stempniewicz

Publikováno v: European Journal of Cancer. 32:S25

Concentrations of CA 15-3 antigen were measured at diagnosis in the sera of 90 node-negative breast cancer women. CA 15-3 values correlated with the higher histological grade (p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71a988c187d6908dc024c0428b0b0bcf
https://doi.org/10.1016/0959-8049(96)84882-9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer.

Autor: Zaborowska-Szmit M; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Szmit S; Department of Cardio-Oncology, Chair of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland. s.szmit@gmail.com.; Department of Cancer Diagnostics and Cardio-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. s.szmit@gmail.com., Olszyna-Serementa M; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Zajda K; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Janowicz-Żebrowska A; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Jaśkiewicz P; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Kowalski DM; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Krzakowski M; Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Publikováno v: Cardio-oncology (London, England) [Cardiooncology] 2024 Nov 09; Vol. 10 (1), pp. 79. Date of Electronic Publication: 2024 Nov 09.

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.

Autor: Reck M; Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de., Dziadziuszko R; Faculty of Medicine, Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan., Kao S; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia., Hochmair M; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna North Hospital Klinik Floridsdorf, Vienna, Austria., Huemer F; Department of Respiratory Care, Ludwig Boltzmann Institute for Lung Health, Klinik Penzing, Vienna, Austria., de Castro G Jr; Clinical Oncology, Instituto de Cancer do Estado de São Paulo, Hospital Das Clínicas Da FMUSP, São Paulo, Brazil., Havel L; First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic., Bernabé Caro R; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain., Losonczy G; Faculty of Medicine, Semmelweis University, Budapest, Hungary., Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Kowalski DM; Department of Lung Cancer and Chest Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Andric Z; Department of Medical Oncology, Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia., Califano R; Department of Medical Oncology, The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, UK., Veatch A; Northwest Medical Specialties, Puyallup, WA, USA., Gerstner G; Illinois Cancer Care, Peoria, IL, USA., Batus M; Medical Oncology, Rush University Medical Center, Chicago, IL, USA., Morris S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Kaul M; Oncology Product Development Safety, Genentech Inc, South San Francisco, CA, USA., Cuchelkar V; Product Development Oncology-Hematology, Genentech, South San Francisco, CA, USA., Li H; Roche, Product Development China, Shanghai, China., Danner BJ; Genentech, South San Francisco, CA, USA., Nabet BY; Computational Sciences, Genentech, South San Francisco, CA, USA., Liu SV; Thoracic Oncology and Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Oct; Vol. 196, pp. 107924. Date of Electronic Publication: 2024 Aug 10.